|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02633 JACOBSON PHARMA
Nominal 
0.830 +0.010 (+1.220%) | 2024/03 - Final HKD(K$) | %Chg (Compare to Final) | 2023/03 HKD(K$) | 2022/03 HKD(K$) | 2021/03 HKD(K$) | 2020/03 HKD(K$) | |
| Turnover | 1,467,798 | -17.797% | 1,785,579 | 1,595,543 | 1,445,915 | 1,571,459 |
| Cost of Sales | (847,323) | -18.402% | (1,038,407) | (975,021) | (884,832) | (881,481) |
| Gross Profit | 620,475 | -16.957% | 747,172 | 620,522 | 561,083 | 689,978 |
| 2024/03 - Final HKD(K$) | %Chg (Compare to Final) | 2023/03 HKD(K$) | 2022/03 HKD(K$) | 2021/03 HKD(K$) | 2020/03 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 165 | -- | (3,560) | (3,768) | (5,527) | 628 | |
| Profit / (Loss) before Taxation | 254,583 | -25.069% | 339,755 | 231,433 | 220,569 | 263,486 | |
| Taxation | (44,414) | -21.455% | (56,546) | (43,728) | (34,264) | (46,025) | |
| Profit / (Loss) from Discontinued Operations | 52,392 | -- | -- | -- | 3 | 1,647 | |
| Non-controlling Interests | (23,810) | -25.975% | (32,165) | (10,039) | (12,595) | (3,477) | |
| Others | 28,217 | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 266,968 | 6.343% | 251,044 | 177,666 | 173,713 | 215,631 | |
| 2024/03 - Final HKD(K$) | %Chg (Compare to Final) | 2023/03 HKD(K$) | 2022/03 HKD(K$) | 2021/03 HKD(K$) | 2020/03 HKD(K$) | |
| Net Finance Costs / (Income) | 54,702 | 10.962% | 49,298 | 23,798 | 28,056 | 49,629 |
| Depreciation & Amortisation | 141,823 | -23.114% | 184,460 | 192,597 | 191,701 | 166,271 |
| Directors' Emoluments | 31,653 | 16.594% | 27,148 | 10,886 | 9,634 | 10,869 |
| 2024/03 - Final | %Chg (Compare to Final) | 2023/03 | 2022/03 | 2021/03 | 2020/03 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/03 - Final | %Chg (Compare to Final) | 2023/03 | 2022/03 | 2021/03 | 2020/03 | |
| EPS (cts) | 13.900 | 5.864% | 13.130 | 9.270 | 9.070 | 10.870 |
| DPS (cts) | 5.500 | -- | 5.180 | 3.880 | 2.300 | 4.500 |
| Dividend Payout Ratio (%) | 39.568% | -- | 39.452% | 41.855% | 25.358% | 41.398% |
| Cash flow per share ($) | 0.252 | -- | 0.330 | 0.212 | 0.214 | 0.182 |
| NBV per share ($) | 1.186 | -- | 1.415 | 1.288 | 1.236 | 1.268 |
| Remarks: | Real time quote last updated: 29/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders ($) | HKD 140,290,000 |
| %Change | -8.926% |
| EPS / (LPS) | HKD 0.071 |
| NBV Per Share ($) | HKD 1.216 |